Clinical Trials Browser

NETWORK × Neoplasms × Fenretinide × Clear all

NCT01553071 2022-03-31

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Phase 1 Terminated

Neoplasms, Recurrence